ID   CCF-RC1
AC   CVCL_9703
SY   CCF-RC-1
DR   Wikidata; Q54808963
RX   PubMed=2582448;
RX   PubMed=7591954;
CC   Population: Caucasian.
CC   Doubling time: 34 hours (PubMed=2582448).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9704 ! CCF-RC2
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 11
//
RX   PubMed=2582448;
RA   Hashimura T., Tubbs R.R., Connelly R., Caulfield M.J., Trindade C.S.,
RA   McMahon J.T., Galetti T.P., Edinger M., Sandberg A.A., Dal Cin P.S.,
RA   Sait S.N.J., Pontes J.E.;
RT   "Characterization of two cell lines with distinct phenotypes and
RT   genotypes established from a patient with renal cell carcinoma.";
RL   Cancer Res. 49:7064-7071(1989).
//
RX   PubMed=7591954; DOI=10.1111/j.1349-7006.1995.tb03087.x; PMCID=PMC5920923;
RA   Kinoshita H., Yamada H., Ogawa O., Kakehi Y., Osaka M., Nakamura E.,
RA   Mishina M., Habuchi T., Takahashi R., Sugiyama T., Yoshida O.;
RT   "Contribution of chromosome 9p21-22 deletion to the progression of
RT   human renal cell carcinoma.";
RL   Jpn. J. Cancer Res. 86:795-799(1995).
//